{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:46:45Z","timestamp":1793969205356,"version":"4.8.0"},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"<jats:sec id=\"ab-noi240049-4\"><jats:title>Importance<\/jats:title><jats:p>Anti-\u03b2-amyloid immunotherapy using lecanemab is becoming increasingly available to patients with Alzheimer disease (AD). Individuals with Down syndrome (DS) develop AD neuropathology by age 40 years, representing a significant cohort of genetically determined AD.<\/jats:p><\/jats:sec><jats:sec id=\"ab-noi240049-5\"><jats:title>Objective<\/jats:title><jats:p>To investigate the binding properties of lecanemab in the brains of people with DS, in anticipation of their inclusion in clinical trials or access to antiamyloid immunotherapies.<\/jats:p><\/jats:sec><jats:sec id=\"ab-noi240049-6\"><jats:title>Design, Setting, Participants<\/jats:title><jats:p>The study included cases of postmortem brain tissue analysis from 15 individuals with DS aged 43 to 68 years that were acquired from Alzheimer Disease research centers at the University of California, Irvine and the University of Kentucky from 2008 to 2021. Data were analyzed from August 2023 through May 2024.<\/jats:p><\/jats:sec><jats:sec id=\"ab-noi240049-7\"><jats:title>Exposure<\/jats:title><jats:p>The binding properties of lecanemab were assessed in brain tissue.<\/jats:p><\/jats:sec><jats:sec id=\"ab-noi240049-8\"><jats:title>Main Outcome<\/jats:title><jats:p>The primary outcome was the extent of lecanemab binding to amyloid plaques and brain blood vessels.<\/jats:p><\/jats:sec><jats:sec id=\"ab-noi240049-9\"><jats:title>Results<\/jats:title><jats:p>Tissue from 15 people (8 were female [53%]) with DS ranging in age from 43 to 68 (mean, 56.6) years were included in the study. Lecanemab-labeled amyloid plaques appeared in all 15 DS cases studied, indicating potential target engagement. However, extensive binding of lecanemab to brain blood vessels in DS was observed, raising significant safety concerns. These findings underscore the necessity for clinical trials of lecanemab in people with DS to evaluate both safety and efficacy, particularly in individuals older than 43 years.<\/jats:p><\/jats:sec><jats:sec id=\"ab-noi240049-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>These findings suggest significant binding of lecanemab to cerebral amyloid angiopathy in DS. Lecanemab should be rigorously tested in clinical trials for AD in the DS population to determine its safety and efficacy, especially in those older than 43 years.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaneurol.2024.2579","type":"journal-article","created":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T15:00:47Z","timestamp":1724079647000},"page":"1066","source":"Crossref","is-referenced-by-count":28,"title":["Lecanemab and Vascular-Amyloid Deposition in Brains of People With Down Syndrome"],"prefix":"10.1001","volume":"81","author":[{"given":"Lei","family":"Liu","sequence":"first","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Saba","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse R.","family":"Pascual","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Department of Neurology, University of California, Irvine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Miller","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth L.","family":"Hennessey","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira T.","family":"Lott","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Department of Neurology, University of California, Irvine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam M.","family":"Brickman","sequence":"additional","affiliation":[{"name":"Taub Institute for Research on Alzheimer\u2019s Disease and the Aging Brain and Department of Neurology, Columbia University, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna M.","family":"Wilcock","sequence":"additional","affiliation":[{"name":"Indiana University School of Medicine, Indianapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan P.","family":"Harp","sequence":"additional","affiliation":[{"name":"Department of Neurology, Sanders-Brown Center on Aging, University of Kentucky, Lexington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick A.","family":"Schmitt","sequence":"additional","affiliation":[{"name":"Department of Neurology, Sanders-Brown Center on Aging, University of Kentucky, Lexington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis J.","family":"Selkoe","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmeer P.","family":"Chhatwal","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"},{"name":"Massachusetts General Hospital, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Head","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Department of Neurology, University of California, Irvine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"11","key":"noi240049r1","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/S1474-4422(21)00245-3","article-title":"Alzheimer\u2019s disease associated with Down syndrome: a genetic form of dementia.","volume":"20","author":"Fortea","year":"2021","journal-title":"Lancet Neurol"},{"issue":"5","key":"noi240049r2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.12910","article-title":"Association of Alzheimer disease with life expectancy in people with Down syndrome.","volume":"5","author":"Iulita","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"22","key":"noi240049r3","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1001\/jama.2023.22924","article-title":"Down syndrome in a new era for Alzheimer disease.","volume":"330","author":"Rafii","year":"2023","journal-title":"JAMA"},{"issue":"11","key":"noi240049r4","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(23)00213-X","article-title":"Compounded inequality: racial disparity and Down syndrome.","volume":"8","author":"McGlinchey","year":"2023","journal-title":"Lancet Public Health"},{"issue":"1","key":"noi240049r5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s40478-017-0499-4","article-title":"Cerebrovascular pathology in Down syndrome and Alzheimer disease.","volume":"5","author":"Head","year":"2017","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"noi240049r6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3233\/JAD-180589","article-title":"Microbleeds and cerebral amyloid angiopathy in the brains of people with Down syndrome with Alzheimer\u2019s Disease.","volume":"67","author":"Helman","year":"2019","journal-title":"J Alzheimers Dis"},{"issue":"11","key":"noi240049r7","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s11910-022-01235-1","article-title":"Vascular considerations for amyloid immunotherapy.","volume":"22","author":"Foley","year":"2022","journal-title":"Curr Neurol Neurosci Rep"},{"key":"noi240049r8","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcn.2021.103641","article-title":"Elevated soluble amyloid beta protofibrils in Down syndrome and Alzheimer\u2019s disease.","volume":"114","author":"Johannesson","year":"2021","journal-title":"Mol Cell Neurosci"},{"issue":"4","key":"noi240049r9","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1002\/acn3.761","article-title":"Immunotherapy with ponezumab for probable cerebral amyloid angiopathy.","volume":"6","author":"Leurent","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"issue":"4","key":"noi240049r10","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","article-title":"Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer\u2019s Association Research Roundtable Workgroup.","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"24","key":"noi240049r11","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1212\/WNL.0000000000200704","article-title":"Cerebral amyloid angiopathy-related inflammation in Down syndrome-related Alzheimer disease.","volume":"98","author":"Aranha","year":"2022","journal-title":"Neurology"},{"issue":"1","key":"noi240049r12","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s11689-022-09435-z","article-title":"Conducting clinical trials in persons with Down syndrome: summary from the NIH INCLUDE Down syndrome clinical trials readiness working group.","volume":"14","author":"Baumer","year":"2022","journal-title":"J Neurodev Disord"},{"issue":"6","key":"noi240049r13","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1001\/jamaneurol.2022.0983","article-title":"Safety, tolerability, and immunogenicity of the ACI-24 Vaccine in adults with Down syndrome: a phase 1b randomized clinical trial.","volume":"79","author":"Rafii","year":"2022","journal-title":"JAMA Neurol"},{"issue":"11","key":"noi240049r14","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.jalz.2017.03.007","article-title":"Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomal-dominant Alzheimer\u2019s disease.","volume":"13","author":"Carmona-Iragui","year":"2017","journal-title":"Alzheimers Dement"},{"issue":"6","key":"noi240049r15","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1002\/ana.25905","article-title":"Alzheimer-related cerebrovascular disease in Down syndrome.","volume":"88","author":"Lao","year":"2020","journal-title":"Ann Neurol"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2822642\/jamaneurology_liu_2024_oi_240049_1727885000.5661.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T15:01:28Z","timestamp":1728918088000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2822642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2024.2579","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,1]]}}}